Is the yellow‑fever vaccine safe for a patient with thyroid cancer, and how do immunosuppressive treatments or radioactive iodine (I‑131) therapy affect vaccination timing?

Yellow Fever Vaccination in Thyroid Cancer Patients

Yellow fever vaccine can generally be administered safely to patients with thyroid cancer, as solid tumors like thyroid cancer do not inherently cause the degree of immunosuppression that contraindicates live vaccines 1.

Key Decision Points

Thyroid Cancer Without Active Treatment

• Patients with thyroid cancer who are not on immunosuppressive therapy can receive yellow fever vaccine without additional precautions
• Thyroid cancer itself (differentiated thyroid carcinoma) does not cause immunosuppression that would contraindicate live attenuated vaccines 1
• The vaccine has been shown safe in patients with solid tumors who are not actively receiving immunosuppressive chemotherapy

Timing Around Radioactive Iodine (I-131) Therapy

Administer yellow fever vaccine either before starting I-131 therapy or wait at least 3-4 weeks after I-131 treatment to allow for optimal immune response.

The radioactive iodine itself does not cause significant immunosuppression, but the practical considerations are:

• I-131 therapy for thyroid cancer uses doses ranging from 1.11 to 7.4 GBq (30-200 mCi) 2
• These doses do not cause the profound immunosuppression seen with chemotherapy
• However, optimal antibody response requires a functioning immune system, so spacing vaccination away from the acute treatment period is prudent

If Patient Is on Immunosuppressive Therapy

This scenario is uncommon in thyroid cancer but may occur if the patient has concurrent autoimmune conditions:

Low-dose immunosuppression (e.g., methotrexate ≤20 mg/week):

• Yellow fever vaccine appears safe and immunogenic 3
• 86% experienced systemic reactions (vs 66% in controls), but no serious adverse events occurred
• All vaccinees achieved seroprotection by Day 28 3

Moderate to high-dose immunosuppression or anti-CD20 therapy:

• Yellow fever vaccine is contraindicated 4
• Case reports document vaccine-associated yellow fever disease in patients on anti-CD20 antibodies 4
• The systematic review found an 8.5% risk of adverse events in immunocompromised individuals, though the relative risk was not significantly elevated (RR 1.00,95% CI 0.78-1.29) 5

Clinical Algorithm

1. Assess current treatment status:

   • No active treatment → Vaccinate without restriction
   • Scheduled for I-131 → Vaccinate before treatment or wait 3-4 weeks after
   • On immunosuppressive therapy → Assess degree of immunosuppression

2. If on immunosuppression:

   • Low-dose methotrexate or similar → Proceed with vaccination under medical supervision
   • Anti-CD20 therapy, high-dose steroids, or combination immunosuppression → Contraindicated

3. If previously vaccinated before immunosuppression:

   • Immunity likely persists even after starting immunosuppressive therapy 6
   • 88% remained seropositive after median 21 years despite immunosuppression 6

Important Caveats

• First-time vaccination carries higher risk of adverse events than booster doses, particularly in immunocompromised patients 1
• The FDA labeling for radioactive iodine 7 addresses potassium iodide (KI) for radiation emergencies, not I-131 therapy for thyroid cancer—these are distinct clinical scenarios
• Yellow fever vaccine adverse events are more common with first doses and in those over 60 years of age 1
• If vaccination must occur during mild immunosuppression, ensure close monitoring for 28 days post-vaccination for signs of vaccine-associated disease 4